Analyst Price Target is $29.14
▲ +142.45% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Oculis in the last 3 months. The average price target is $29.14, with a high forecast of $35.00 and a low forecast of $23.00. The average price target represents a 142.45% upside from the last price of $12.02.
Current Consensus is
Buy
The current consensus among 9 contributing investment analysts is to buy stock in Oculis. This Buy consensus rating has held steady for over two years.
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Read More